30.70
                                            전일 마감가:
              $30.82
            열려 있는:
              $30.7
            하루 거래량:
                2.02M
            Relative Volume:
              1.02
            시가총액:
                $5.07B
            수익:
              $1.51B
            순이익/손실:
              $333.35M
            주가수익비율:
              15.74
            EPS:
                1.95
            순현금흐름:
                $315.22M
            1주 성능:
              +3.02%
            1개월 성능:
              +2.33%
            6개월 성능:
                +6.71%
            1년 성능:
              +19.46%
            Alkermes Plc Stock (ALKS) Company Profile
명칭
                  
                      Alkermes Plc
                    
                전화
                  
                      00-353-1-772-8000
                    
                주소
                  
                      CONNAUGHT HOUSE, DUBLIN 4
                    
                ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 | 
|---|---|---|---|---|---|---|
|   
                          
                                ALKS
                            
                             Alkermes Plc | 30.70 | 5.09B | 1.51B | 333.35M | 315.22M | 1.95 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 | 
|---|---|---|---|
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform | 
| 2025-09-03 | 개시 | Wells Fargo | Overweight | 
| 2025-07-15 | 개시 | Goldman | Buy | 
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy | 
| 2025-05-28 | 개시 | Needham | Buy | 
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform | 
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral | 
| 2025-02-11 | 개시 | Deutsche Bank | Buy | 
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy | 
| 2024-06-17 | 개시 | TD Cowen | Buy | 
| 2024-03-19 | 개시 | Robert W. Baird | Outperform | 
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell | 
| 2023-11-20 | 재개 | JP Morgan | Neutral | 
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform | 
| 2023-10-17 | 개시 | UBS | Neutral | 
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight | 
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral | 
| 2022-08-16 | 개시 | Piper Sandler | Neutral | 
| 2022-04-22 | 재개 | Goldman | Buy | 
| 2022-04-20 | 개시 | Goldman | Buy | 
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight | 
| 2021-12-01 | 개시 | Citigroup | Neutral | 
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy | 
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform | 
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy | 
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell | 
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral | 
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral | 
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral | 
| 2020-02-06 | 개시 | Mizuho | Neutral | 
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform | 
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight | 
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral | 
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral | 
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral | 
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell | 
| 2018-12-14 | 개시 | Wolfe Research | Underperform | 
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform | 
| 2018-11-05 | 개시 | Piper Jaffray | Neutral | 
| 2018-08-07 | 개시 | Stifel | Hold | 
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight | 
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy | 
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy | 
| 2018-05-11 | 개시 | BofA/Merrill | Buy | 
                    모두보기
                     
                  
                Alkermes Plc 주식(ALKS)의 최신 뉴스
Why Alkermes plc stock appeals to analystsBuy Signal & Safe Capital Investment Plans - newser.com
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Can Alkermes plc stock deliver consistent earnings growthMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com
Exit strategy if you’re trapped in Alkermes plc2025 Price Momentum & Smart Investment Allocation Tips - newser.com
Price momentum metrics for Alkermes plc explainedDay Trade & Technical Pattern Based Signals - newser.com
What moving averages say about Alkermes plcJuly 2025 Trade Ideas & Daily Market Momentum Tracking - newser.com
Real time social sentiment graph for Alkermes plcBuy Signal & Free Accurate Trade Setup Notifications - newser.com
What to do if you’re stuck in Alkermes plcQuarterly Trade Summary & Risk Managed Investment Signals - newser.com
How resilient is Alkermes plc stock in market downturnsTrade Volume Report & Fast Momentum Stock Entry Tips - newser.com
Is Alkermes plc (8AK) stock a safe buy pre earnings2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
What recovery options are there for Alkermes plcQuarterly Investment Review & Community Trade Idea Sharing - newser.com
Is Alkermes plc forming a bottoming baseWeekly Profit Analysis & Stock Portfolio Risk Management - newser.com
Alkermes Q3 2025 Earnings: Strong Growth & Strategic Moves - TipRanks
Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Investing.com Canada
Alkermes (NASDAQ:ALKS) Price Target Cut to $42.00 by Analysts at Wells Fargo & Company - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $44.00 - MarketBeat
Alkermes Plc Experiences Evaluation Revision Amid Mixed Technical Indicators and Performance Trends - Markets Mojo
Why Alkermes plc stock is seen as undervalued2025 Big Picture & AI Forecasted Stock Moves - newser.com
Order flow analysis tools used on Alkermes plc2025 Performance Recap & Entry Point Strategy Guides - newser.com
What technical patterns form on Alkermes plc (8AK) stock chartsAnalyst Upgrade & High Accuracy Swing Trade Signals - newser.com
Applying Wyckoff theory to Alkermes plc stockEarnings Summary Report & Real-Time Buy Signal Alerts - newser.com
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised - The Globe and Mail
Alkermes (ALKS) Maintains Overweight Rating as Wells Fargo Lowers Price Target | ALKS Stock News - GuruFocus
Deutsche Bank Adjusts Alkermes Price Target to $55 From $53, Maintains Buy Rating - MarketScreener
Alkermes (NASDAQ:ALKS) Announces Quarterly Earnings Results - MarketBeat
Alkermes (NASDAQ:ALKS) Releases FY 2025 Earnings Guidance - MarketBeat
Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call Transcript - Insider Monkey
Needham Maintains Buy Rating for ALKS, Raises Price Target | ALKS Stock News - GuruFocus
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates - sharewise.com
Y Intercept Hong Kong Ltd Increases Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Sold by Allianz Asset Management GmbH - MarketBeat
Alkermes’ Acquisition of Avadel Faces Uncertainty Amid Regulatory and Financial Hurdles - TipRanks
Alkermes plc Reports Strong Q3 2025 Results - TipRanks
Decoding Alkermes PLC (ALKS): A Strategic SWOT Insight - GuruFocus
Relative strength of Alkermes plc in sector analysisQuarterly Earnings Summary & Weekly Momentum Stock Picks - newser.com
Alkermes: Q3 Earnings Snapshot - Stamford Advocate
Alkermes Plc earnings beat by $0.11, revenue topped estimates - Investing.com Australia
Alkermes Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Alkermes beats Q3 2025 expectations, shares rise By Investing.com - Investing.com Nigeria
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Alkermes Lifts Outlook After Beating Revenue Targets - Finimize
Alkermes plc. SEC 10-Q Report - TradingView
Earnings call transcript: Alkermes beats Q3 2025 expectations, shares rise - Investing.com
Alkermes (ALKS) Surpasses Revenue Expectations in Q3, Sets Sights on Future Growth - GuruFocus
Alkermes shares rise 5% as third quarter results top expectations By Investing.com - Investing.com Australia
Earnings Flash (ALKS) Alkermes plc Reports Q3 Revenue $394.2M, vs. FactSet Est of $356.9M - MarketScreener
Alkermes PLC Q3 2025 Earnings: EPS of $0.49 and Revenue of $394. - GuruFocus
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alkermes Plc 주식 (ALKS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 | 
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Oct 15 '25 | Sale | 31.53 | 9,000 | 283,776 | 73,740 | 
                자본화:
                 
                  | 
                볼륨(24시간):
                 
            
         
                     
                             Stockscreener 앱 받기
                    Stockscreener 앱 받기